Fluphenazine Decanoate, Fluphenazine Hydrochloride Given Orally, and Placebo in Remitted Schizophrenics

Rifkin, Arthur; Quitkin, F; Rabiner, Charles J.; Klein, Donald F.

doi:10.1001/archpsyc.1977.01770130045004

Cited by 159 publications

(50 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the difference was minimal. Rißein et al (13) noted retarded depression needing discontinuation of medication was 35% in the decanoate group and nil in the oral fluphenazine group.…”

Section: Phenothiazinesmentioning

confidence: 96%

Drug-Induced Mood Disorders

Ananth¹,

Ghadirian²

1980

Int Pharmacopsychiatry

View full text Add to dashboard Cite

Various drugs including antihypertensives, anxiolytics, antibiotics, antidepressants, corticosteroids, choline, indomethacin, levodopa, metronidazole, neuroleptics, oral contraceptives, sulphonamides and physostigmine have been reported to produce depression as a side effect. Clinically, these drug-induced depressions may go unnoticed and thus create therapeutic problems. Although causal relationship is difficult to establish, depression occurring during the course of drug treatment needs an evaluation of all the medications that the patient has been receiving. We believe that postpsychotic depressions include three types of depression: pendular depression — primarily disease related; chronic depression - primarily environment related, and amine-depletion depression - drug related. Thus, drug-induced depressions constitute a subgroup of postpsychotic depression. Clinically, it is essential to carefully monitor patients receiving drugs known to produce depression. Thus, prompt recognition of the drug-induced depressions may assist in initiating proper therapeutic measures.

show abstract

Section: Phenothiazinesmentioning

confidence: 96%

Drug-Induced Mood Disorders

Ananth¹,

Ghadirian²

1980

Int Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

“…Mit Einführung der Neuroleptika in die Behandlung schizophrener Psychosen Anfang der 50er Jahre konnten zum Teil langjährig hospitalisierte Patienten entlassen werden (¹Dein-stitutionalisierungª), mussten aber häufig wieder aufgenommen werden (¹Drehtür-Effektª [32,58]. Diese Befunde betonen das besonders gute Behandlungsansprechen bei günstiger prognostischer Ausgangssituation [42].…”

Section: Krankheitsverlauf Und Behandlungsergebnisseunclassified

Strategien der pharmakologischen Langzeitbehandlung schizophrener Störungen

Gaebel¹

2001

Fortschr Neurol Psychiatr

View full text Add to dashboard Cite

Schizophrenia is a relapsing disorder. The main goal of neuroleptic long-term treatment is relapse prevention, which is empirically well proven. Availability of different kinds of treatment strategies including new antipsychotic drugs with improved risk/benefit profile allow long-term treatment to be individually tailored. Treatment guidelines developed mainly by the scientific medical societies can help the practitioner in making the right decisions.

show abstract

“…Ook hier zijn de resultaten weer sterk wisselend. Sommige onderzoeken lieten dramatische verschillen zien in het percentage terugval, bijvoorbeeld, na e´e´n jaar, bij het gebruik van een placebo 68% en bij het gebruik van een antipsychoticum 7% (Rifkin, Quitkin, Rabiner & Klein, 1977 ;N = 62). In het Northwick Parkonderzoek waren, na twee jaar, de verhoudingen 62% tegen 46% (N = 120; Crow et al, 1986).…”

Section: Langdurige Profylactische Behandelingunclassified

De (in)effectiviteit van psychofarmaca

Burg¹

1998

DITH

View full text Add to dashboard Cite

Fluphenazine Decanoate, Fluphenazine Hydrochloride Given Orally, and Placebo in Remitted Schizophrenics

Cited by 159 publications

References 12 publications

Drug-Induced Mood Disorders

Drug-Induced Mood Disorders

Strategien der pharmakologischen Langzeitbehandlung schizophrener Störungen

De (in)effectiviteit van psychofarmaca

Contact Info

Product

Resources

About